FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225538620> ?p ?o ?g. }

• W4225538620 abstract "Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease affecting people older than 50, resulting in pain and stiffness of the neck, shoulder, and pelvic girdle. To date, glucocorticoids (GC) remain the cornerstone of treatment, but these have several drawbacks. Firstly, a large proportion of patients do not achieve GC-free remission within either the first (over 70%) or second year of treatment (over 50%). Secondly, GC-related adverse events (AE) occur in up to 65% of patients and can be severe. The current EULAR/ACR guidelines for PMR recommend early introduction of methotrexate (MTX) as a GC sparing agent in patients at risk for worse prognosis. However, earlier trials of low to medium quality only studied MTX dosages of 7.5-10 mg/week with no to modest effect. These doses may be suboptimal as MTX is recommended in higher doses (25 mg/week) for other inflammatory rheumatic diseases. The exact role, timing, and dose of MTX in PMR remain unclear, and therefore, our objective is to study the efficacy of MTX 25 mg/week in recently diagnosed PMR patients.We set up a double-blind, randomized, placebo-controlled superiority trial (PMR MODE) to assess the efficacy of MTX 25 mg/week versus placebo in a 1:1 ratio in 100 recently diagnosed PMR patients according to the 2012 EULAR/ACR criteria. All patients will receive prednisolone 15 mg/day, tapered to 0 mg over the course of 24 weeks. In case of primary non-response or disease relapse, prednisolone dose will be temporarily increased. Assessments will take place at baseline, 4, 12, 24, 32, and 52 weeks. The primary outcome is the difference in proportion of patients in GC-free remission at week 52.No relapsing PMR patients were chosen, since the possible benefits of MTX may not outweigh the risks at low doses and effect modification may occur. Accelerated tapering was chosen in order to more easily identify a GC-sparing effect if one exists. A composite endpoint of GC-free remission was chosen as a clinically relevant endpoint for both patients and rheumatologist and may reduce second order (treatment) effects.Dutch Trial Registration, NL8366 . Registered on 10 February 2020." @default.
• W4225538620 created "2022-05-05" @default.
• W4225538620 creator A5030365370 @default.
• W4225538620 creator A5034163934 @default.
• W4225538620 creator A5056524975 @default.
• W4225538620 creator A5066283044 @default.
• W4225538620 creator A5090181676 @default.
• W4225538620 date "2022-04-15" @default.
• W4225538620 modified "2023-09-27" @default.
• W4225538620 title "PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial" @default.
• W4225538620 cites W140779711 @default.
• W4225538620 cites W1774118966 @default.
• W4225538620 cites W1908060123 @default.
• W4225538620 cites W1971672948 @default.
• W4225538620 cites W1983403395 @default.
• W4225538620 cites W2013864512 @default.
• W4225538620 cites W2032686039 @default.
• W4225538620 cites W2034248891 @default.
• W4225538620 cites W2050116365 @default.
• W4225538620 cites W2071326876 @default.
• W4225538620 cites W2076498186 @default.
• W4225538620 cites W2084214906 @default.
• W4225538620 cites W2086598637 @default.
• W4225538620 cites W2100651899 @default.
• W4225538620 cites W2105240332 @default.
• W4225538620 cites W2120197181 @default.
• W4225538620 cites W2120393706 @default.
• W4225538620 cites W2122641956 @default.
• W4225538620 cites W2126269417 @default.
• W4225538620 cites W2141706104 @default.
• W4225538620 cites W2148370712 @default.
• W4225538620 cites W2180244775 @default.
• W4225538620 cites W2288762703 @default.
• W4225538620 cites W2290444582 @default.
• W4225538620 cites W2302501749 @default.
• W4225538620 cites W2334353679 @default.
• W4225538620 cites W2427523709 @default.
• W4225538620 cites W2504775069 @default.
• W4225538620 cites W2527887155 @default.
• W4225538620 cites W2537085646 @default.
• W4225538620 cites W2618637353 @default.
• W4225538620 cites W2767898276 @default.
• W4225538620 cites W2898053476 @default.
• W4225538620 cites W2971561167 @default.
• W4225538620 cites W3014493104 @default.
• W4225538620 cites W3110306240 @default.
• W4225538620 cites W3150548516 @default.
• W4225538620 cites W3200897600 @default.
• W4225538620 cites W4211106135 @default.
• W4225538620 cites W4294350876 @default.
• W4225538620 cites W67729577 @default.
• W4225538620 cites W82351800 @default.
• W4225538620 doi "https://doi.org/10.1186/s13063-022-06263-3" @default.
• W4225538620 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35428320" @default.
• W4225538620 hasPublicationYear "2022" @default.
• W4225538620 type Work @default.
• W4225538620 citedByCount "4" @default.
• W4225538620 countsByYear W42255386202022 @default.
• W4225538620 countsByYear W42255386202023 @default.
• W4225538620 crossrefType "journal-article" @default.
• W4225538620 hasAuthorship W4225538620A5030365370 @default.
• W4225538620 hasAuthorship W4225538620A5034163934 @default.
• W4225538620 hasAuthorship W4225538620A5056524975 @default.
• W4225538620 hasAuthorship W4225538620A5066283044 @default.
• W4225538620 hasAuthorship W4225538620A5090181676 @default.
• W4225538620 hasBestOaLocation W42255386201 @default.
• W4225538620 hasConcept C126322002 @default.
• W4225538620 hasConcept C141071460 @default.
• W4225538620 hasConcept C142724271 @default.
• W4225538620 hasConcept C168563851 @default.
• W4225538620 hasConcept C197934379 @default.
• W4225538620 hasConcept C204787440 @default.
• W4225538620 hasConcept C27081682 @default.
• W4225538620 hasConcept C2776015282 @default.
• W4225538620 hasConcept C2776712624 @default.
• W4225538620 hasConcept C2776715498 @default.
• W4225538620 hasConcept C2779134260 @default.
• W4225538620 hasConcept C2780079024 @default.
• W4225538620 hasConcept C2781059491 @default.
• W4225538620 hasConcept C535046627 @default.
• W4225538620 hasConcept C71924100 @default.
• W4225538620 hasConceptScore W4225538620C126322002 @default.
• W4225538620 hasConceptScore W4225538620C141071460 @default.
• W4225538620 hasConceptScore W4225538620C142724271 @default.
• W4225538620 hasConceptScore W4225538620C168563851 @default.
• W4225538620 hasConceptScore W4225538620C197934379 @default.
• W4225538620 hasConceptScore W4225538620C204787440 @default.
• W4225538620 hasConceptScore W4225538620C27081682 @default.
• W4225538620 hasConceptScore W4225538620C2776015282 @default.
• W4225538620 hasConceptScore W4225538620C2776712624 @default.
• W4225538620 hasConceptScore W4225538620C2776715498 @default.
• W4225538620 hasConceptScore W4225538620C2779134260 @default.
• W4225538620 hasConceptScore W4225538620C2780079024 @default.
• W4225538620 hasConceptScore W4225538620C2781059491 @default.
• W4225538620 hasConceptScore W4225538620C535046627 @default.
• W4225538620 hasConceptScore W4225538620C71924100 @default.
• W4225538620 hasFunder F4320323768 @default.
• W4225538620 hasIssue "1" @default.
• W4225538620 hasLocation W42255386201 @default.
• W4225538620 hasLocation W42255386202 @default.

• next